Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro (Q59096959)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

title

Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

main subject

multiple drug resistance

1 reference

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

Larder BA

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

Kemp SD

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

language of work or name

English

0 references

publication date

1 September 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

volume

365

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

issue

6445

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

page(s)

451-453

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7692302%20AND%20SRC:MED&resulttype=core&format=json

HIV inhibitors targeted at the reverse transcriptase

23 October 2019

cites work

1 reference

7 January 2021

Site-specific mutagenesis of AIDS virus reverse transcriptase

1 reference

7 January 2021

Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity

1 reference

7 January 2021

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

7 January 2021

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy

1 reference

7 January 2021

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

1 reference

7 January 2021

Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay

1 reference

7 January 2021

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

1 reference

7 January 2021

HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase

1 reference

7 January 2021

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

1 reference

7 January 2021

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

1 reference

7 January 2021

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

7 January 2021

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

1 reference

7 January 2021

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine

1 reference

7 January 2021

Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity

1 reference

7 January 2021

Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro

1 reference

7 January 2021

Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay

1 reference

7 January 2021

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

1 reference

7 January 2021

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy

1 reference

7 January 2021

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

1 reference

7 January 2021

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

7 January 2021

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

7 January 2021

HIV and multidrug resistance

1 reference

7 January 2021

1 reference

7 January 2021